Saturday 17 October 2026
Export RARE’s income statement to Excel — free account
Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
14.54
0.63
−4.15%
Follow RARE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.75 | 3.15 | 3.37 | 4.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(35.08) | (10.70) | (22.72) | (32.92) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 327.67 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.34 | 2.53 | 2.36 | 4.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.41) | (3.41) | (3.41) | (5.78) | |
EV/FCF |
(6.30) | (3.34) | (3.26) | (5.53) | |
Quick Ratio |
1.40 | 1.64 | 2.18 | 1.58 | |
Current Ratio |
1.73 | 2.02 | 2.48 | 1.89 | |
Net Debt/EBITDA |
4.36 | 2.55 | 6.49 | 2.61 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.56 | 0.51 | 0.44 | 0.46 | |
Operating CF/Net income |
1.05 | 1.06 | 0.78 | 0.51 | |
Capex/Depreciation |
(0.12) | (0.86) | (0.11) | (0.14) | |
Interest Coverage |
(3.41) | (8.05) | (5.70) | (12.08) | |
Research and Development Expense of Revenue |
78.04% | 137.50% | 97.93% | 135.19% | |
Selling, General and Administrative Expense of Revenue |
41.12% | 64.71% | 42.68% | 54.16% | |
Intangible Assets out of Total Assets |
0.17 | 0.17 | 0.14 | 0.18 | |
Share Based Compensation of Revenue |
15.89% | 22.06% | 18.01% | 23.58% | |
Graham Net Nets |
(0.28) | (0.42) | (0.29) | (0.18) | |
Graham Number |
19.37 | 17.96 | 10.33 | 0.00 | |
Earnings Yield |
(17.49%) | (29.16%) | (25.39%) | (19.75%) | |
Free Cash Flow Yield |
(14.52%) | (24.10%) | (21.47%) | (15.53%) | |
Revenue per Share |
2.10 | 1.35 | 2.10 | 1.60 | |
Operating CF per Share |
(0.95) | (1.96) | (1.01) | (0.91) | |
Capex per Share |
(0.01) | (0.06) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.96) | (2.02) | (1.02) | (0.92) | |
Cash per Share |
2.87 | 4.11 | 6.90 | 4.26 | |
Shareholders Equity per Share |
(2.86) | (2.35) | (0.81) | 0.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.86) | (2.35) | (0.81) | 0.09 | |
Free Cash Flow |
(98.00) | (203.00) | (100.77) | (92.23) | |
Working Capital |
255.00 | 332.00 | 567.00 | 303.18 | |
Capital Expenditures |
(1.00) | (6.00) | (0.94) | (1.06) | |
Net Current Asset Value |
(949.00) | (875.00) | (661.00) | (538.08) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
162.23 | 109.92 | 140.00 | 102.92 | |
Average Payables |
36.62 | 44.73 | 35.00 | 38.28 | |
Average Inventory |
52.75 | 50.52 | 48.50 | 47.77 | |
Average Assets |
1,285.13 | 1,303.96 | 1,517.50 | 1,364.40 | |
Average Common Equity |
(69.86) | (45.88) | 87.50 | 177.99 |
Columns are period end dates